

BioScrip, Inc.  
Form 8-K  
March 12, 2007

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C.**

**FORM 8-K  
CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934  
Date of Report (Date of earliest event reported): March 7, 2007  
BioScrip, Inc.  
(Exact Name of Registrant as Specified in its Charter)**

**Delaware**  
(State or Other Jurisdiction of  
Incorporation)

**0-28740**  
(Commission  
File Number)

**05-0489664**  
(IRS Employer  
Identification No.)

**100 Clearbrook Road, Elmsford, New York**  
(Address of Principal Executive Offices)  
Registrant's telephone number, including area code **(914) 460-1600**

**10523**  
(Zip Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
  - .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240-14d-2(b)).
  - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
-

**TABLE OF CONTENTS**

Item 1.01 Entry Into a Material Definitive Agreement.

Item 9.01 Financial Statements and Exhibits.

**SIGNATURES**

**EX-10.1: FORM OF EIGHTH AMENDMENT TO RECEIVABLES PURCHASE AND TRANSFER AGREEMENT**

---

**Table of Contents**

**Item 1.01 Entry Into a Material Definitive Agreement.**

On March 7, 2007, BioScrip, Inc., through its subsidiaries BioScrip PBM Services, LLC, BioScrip Pharmacy Services, Inc., BioScrip Infusion Services, Inc., BioScrip Pharmacy (NY), Inc., BioScrip Pharmacy, Inc., Natural Living, Inc. and BioScrip Infusion Services, LLC (collectively, the *Providers* ), entered into an Eighth Amendment, effective as of December 29, 2006, to its Receivables Purchase and Transfer Agreement, dated as of November 1, 2000 (the *RPTA* ), among the Providers and MIM Funding LLC (the *Purchaser* ), which was consented to by BioScrip, Inc. and HFG Healthco-4 LLC, an affiliate of Healthcare Finance Group, Inc. ( *HFG* ). The Amendment modified the method of calculating Consolidated Net Worth and Consolidated EBITDA.

The foregoing summary is qualified in its entirety by reference to the complete text of the Eighth Amendment to the RPTA, a copy of which is attached as Exhibit 10.1 hereto.

**Item 9.01 Financial Statements and Exhibits.**

(c) Exhibits. The following are furnished as exhibits to this Current Report:

Exhibit No.	Description of Exhibit
10.1	Form of Eighth Amendment to the Receivables Purchase and Transfer Agreement

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned duly authorized.

Date: March 12, 2007

BIOSCRIP, INC.

By: /s/ Barry A. Posner  
Barry A. Posner,  
Executive Vice President, Secretary  
and General Counsel

3